Boardroom Alpha
Boardroom Alpha
VIVS · Additional Proxy Materials (DEFA14A) · Filed November 3, 2025

Vivosim Labs Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
November 3, 2025
Ticker
VIVS
Accession
0001193125-25-262551
Boardroom Alpha · Filing insights

VivoSim relays Organovo board’s endorsements on five proposals, including director elections and compensation actions.

About Vivosim Labs Inc
Market cap
$3M
1Y TSR
−18.9%
3Y TSR
−60.0%
Board grade
C-
Sector
Healthcare
CEO
Keith Murphy
Last annual meeting: Dec 16, 2025 · View full Vivosim Labs Inc profile →
DEFA14A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant Filed by a Party other than the Registrant

Check the appropriate box:

 

 

 

Preliminary Proxy Statement

 

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

 

Definitive Proxy Statement

 

 

Definitive Additional Materials

 

 

Soliciting Material under §240.14a-12

VivoSim Labs, Inc.

(Name of Registrant as Specified In Its Charter)

Not Applicable

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required.

 

 

 

 

 

Fee paid previously with preliminary materials.

 

 

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 

 


 

img22547606_0.jpg

Your Vote Counts! ORGANOVO HOLDINGS, INC. 2023 Annual Meeting Vote by October 30, 2023 11:59 PM ET ORGANOVO HOLDINGS, INC. 11555 SORRENTO VALLEY ROAD, SUITE 100 SAN DIEGO, CA 92121 V23261-P98852 You invested in ORGANOVO HOLDINGS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on October 31, 2023. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to October 17, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Vote Virtually at the Meeting* October 31, 2023 9:00 a.m. Pacific Time Smartphone users Point your camera here and vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/ONVO2023 *Please check the meeting materials for any special requirements for meeting attendance. V1.2

 

 


 

img22547606_1.jpg

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. To elect each of Keith Murphy and Adam Stern as a Class III director to hold office until the 2026 Annual Meeting of Stockholders and until his respective successor is elected and qualified. Nominees: For 1a. Keith Murphy 1b. Adam Stern For 2. To ratify the appointment of Rosenberg Rich Baker Berman P.A. as our independent registered public accounting firm for the fiscal year ending March 31, 2024. For For 3. To approve, on an advisory basis, the compensation of our named executive officers. For 4. To approve the Organovo Holdings, Inc. 2023 Employee Stock Purchase Plan. 5. To approve an amendment to our Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V23262-P98852

 


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Vivosim Labs Inc (VIVS)

Reference

Frequently asked questions

When did Vivosim Labs Inc file this DEFA14A?
Vivosim Labs Inc (VIVS) filed this Additional Proxy Materials (DEFA14A) with the SEC on November 3, 2025. The accession number assigned by EDGAR is 0001193125-25-262551.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
VivoSim relays Organovo board’s endorsements on five proposals, including director elections and compensation actions. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Vivosim Labs Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Vivosim Labs Inc has filed under CIK 1497253, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer